The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …

Objective To systematically review the studies exploring the association between
bevacizumab and neurodevelopmental outcomes. Methods Embase, Medline, CINAHL, and …

Purpose To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB)
therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB …

Treatment complications are substantially different for the two modalities in common use
today. In more severe cases, risk of poor structural outcome and myopia favour treatment …

Over the past decade there has been a paradigm shift in the treatment of retinopathy of
prematurity (ROP) with the introduction of antivascular endothelial growth factor (anti-VEGF) …

Background Retinopathy of Prematurity (ROP) and abnormal brain development share
similar risk factors and mechanisms. There has been contrasting evidence on the …

Purpose To synthesize existing evidence on adverse events, complications, and
unfavorable outcomes of current treatment modalities for treatment-requiring retinopathy of …

The current treatment for ocular pathological angiogenesis mainly focuses on anti-VEGF
signals. This treatment has been confirmed as effective despite the unfavorable side effects …

The literature has varied definitions of reactivation, which is often used interchangeably with
recurrence. It is important to recognize features of reactivation of ROP to appropriately …

Retinopathy of prematurity (ROP) is a blinding morbidity of preterm infants, which represents
a significant clinical problem, accounting for up to 40% of all childhood blindness. ROP …